Jan 16, 2024 8:30 am EST NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
Jan 08, 2024 8:30 am EST NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
Jan 03, 2024 8:30 am EST NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
Dec 21, 2023 8:30 am EST NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
Dec 18, 2023 8:30 am EST NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
Dec 12, 2023 8:30 am EST NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets